
Index

- absolute-income hypothesis 5, 15
access to health care xi–xii
 ACSH rates as measure of 55–8, 60
 factors affecting 113–14
 generic, in USA 209
 potential policy action 14
 and social services 233, 240, 242–3, 252
 and socioeconomic status 35–46
 unmet need/forgone care 115–23
ACCORD scheme 169
acute ACSCs 54
acute care
 costs and proximity to death 221–5, 227–8
 NHS responsibility for 234–5
acute myocardial infarction (AMI) studies
 89–90, 141
Adams Dudley, R. 148, 149, 150, 152
Aday, L. 113, 114
administrative barriers 233–4, 246, 249–50
adverse selection 151, 152, 167, 262–3
affect heuristics 300–301
ageing population 136–7, 221–2, 225, 229, 263
Agency for Healthcare Research and Quality
 (AHRQ) 53, 55
Allais, M. 298, 299
Allin, S. 114, 120
Alma-Ata Declaration 20, 21–2, 31–2
Alvarez-Rosete, A. 104, 106
Alzheimer's disease 289–92
ambulatory care xii
 definition 50–51
 measuring quality of 51–3
ambulatory care sensitive conditions (ACSCs)
 conceptual framework for 57
 definitions 53
 factors associated with 56–60
 hospitalisations for 53–5
 summary of studies 64–75
 use by policy makers 60–61
Andersen, R.M. 36–7, 44, 56, 57, 113, 114, 130
Andersson, H. 303, 309, 310
Ansari, Z. 53, 54, 55, 56, 60, 68–9
Appleby, J. 97, 99, 101, 104, 106, 108
Armour, B.S. 147, 154
Arrow, K.J. 85, 107, 315, 316, 318
Association of British Insurers 259, 261
Atkinson, A. 13, 113
Audit Commission 237, 245
autonomy and choice 81–2
avoidable mortality 54
avoided waiting value 107–8
Baker, G. 146, 147
Baker, L.C. 186, 190
Banks, J. 9, 102
Barr, D.A. 90, 91
Barr, N. 260, 261, 263, 272, 274, 276
Barron, P. 22, 23
Barros, P.P. 141, 221
Basu, J. 56, 57
Batljan, I. 223, 225, 228
Baumol effect 136
Baumol, W. 134, 135
Bayesian learning framework 184, 187, 303–6,
 308
Beaulieu, N.D. 148, 149, 150, 153
bed blockers 101, 237
behavioural economics 273, 310, 318
Bell, D. 242, 243, 252
Benham, L. 44, 131
Bennett, S. 163, 168, 170
Benyamini, Y. 8, 114
Berthiaume, J.T. 147, 149, 154
Berwick, D.M. 144, 185
Bevan, G. 79, 83, 88, 98, 99, 105, 106, 108
Beveridge model of health care 87–8, 95–6
Billings, J. 53, 54
Bindman, A.B. 65, 73–4
biomarkers 9–10
Birrell, D. 246, 250, 253
Bismarck model of health care 88
Bokhour, B.G. 144, 146, 147
Booth, H. 292, 293
Bound, J. 5, 9
Bowes, A. 242, 249
Breyer, F. 182, 183, 223, 228
Bridgen, P. 236, 237
Britten, N. 315, 317
Brock, A. 284, 286
Brockmann, H. 222, 229
Brodsky, J. 239, 240
Brown, J.R. 259, 262–6, 269–70, 274–5
Busse, R. 164, 165
Cabiedes, L. 79, 86, 88
Cameron, A. 247, 249

- Cameron, P.A. 147, 149, 154
 Campbell, C. 20–21, 23–8, 30
 Campbell, J.C. 234, 241, 242
 Carrin, G. 160, 169, 170
 Castles, F.G. 39, 45
 cause-of-death approach 283–93
 Chang, C.F. 56, 57, 58, 64
 Chang, S.W. 182, 183
 Charles, C. 316, 317
 Charlton, J. 283, 284, 285, 286
 choice in health care xii, 79–80, 91–2
 defining choice 80–81
 evidence on effects of 88–91
 extrinsic values of 83–6
 intrinsic arguments for 81–3
 policies for introduction of 86–8
 choice of provider, satisfaction with 321
 Christianson, J.B. 144, 146, 147, 148, 149, 155
 chronic ACSCs 54
 co-payments 81, 83, 165, 169, 236, 259, 263
 cognitive biases 12, 300–301, 305, 308–9
 Collins, S. 239, 244, 245
 Colombier, C. 229, 230
 Comas-Herrera, A. 233, 236, 258
 combined long-term care and life insurance 268
 Commission for Social Care Inspection 236, 238
 Commonwealth Fund International Health Policy Survey 11, 123, 144
 community-based health insurance (CBHI) 168, 169, 170
 community health financing schemes 168
 purchasing and provision of health care 170
 revenue collection 168–9
 risk pooling 169–70
 community health worker (CHW) programmes 21
 building external support 26–7, 28–9, 32
 building internal support 25–6, 28, 32
 building skills and confidence 24–5, 28, 32
 community health workers (CHWs) 20
 payment and training 30
 provision of care 23–4
 public sector support for 30–31
 community participation in South Africa xi–xii, 20–32
 competition xii
 in drug market 196
 generic 203, 207, 210, 214
 see also choice in health care
 compulsory private insurance 273–4
 computed tomography (CT) 185–6
 concentration curve (CC) for ill health 6
 concentration index (CI)
 for ill health 6–7
 for unmet need 120
 Conrad, D.A. 144, 147, 149, 150, 151, 154, 155
 consultants' contracts of employment 102–3
 consultation, satisfaction with 321
 continuing care framework 238–9
 Contoyannis, P. 5, 8
 Cooper, Z. 86, 89, 90, 122
 coronary artery bypass graft (CABG) 139, 141, 187–8, 189, 190
 Coscelli, A. 184, 187
 Costa-Font, J. 12, 108, 303
 costs
 containment in European care systems 87
 controlling 140–141
 and efficiency 83–4
 and forgoing care 117, 122
 health care technologies 138–9, 182–3
 and income, role of 130–136
 of long-term care 260–261
 and patient behaviour 99–100, 104
 of private long-term care insurance 263, 264, 271
 and proximity to death 221–30
 and unmet need 116
 Courbage, C. 262, 265, 266, 271, 275
 Coxon, K. 247, 248
 Cramer, A.T. 266, 270, 271, 275
 Crawford, G.S. 184, 187
 cream skimming 84, 86, 140, 167
 Criel, B. 169, 170
 Cullis, J.G. 95, 97, 107
 Cutler, D.M. 139, 179, 185–90, 227
 Dalstra, J.A. 11, 12
 Danzon, P.M. 195, 197, 198, 204
 data and measurement systems for P4P 151–3, 154
 data requirements for measuring health equity 7–12
 Davies, P. 169, 170
 de Castries, H. 273, 274
 death, proximity to, and costs of health care xiv
 decline in costs 229–30
 determinants of cost 221–2
 early studies 222–3
 projections of care use and costs 226–9
 proximity or time? 225–6
 recent studies 223–4
 social care costs 224–5
 Deaton, A.S. 5, 8, 45
 decision behaviour 100

- decision-making 298–9, 301–3, 317
 Delbanco, S. 146, 147
 demand barriers to long-term care insurance 263
 high costs and poor affordability 264
 low preference for 265–6
 mistrust of private insurers 266
 risk perception 264–5
 demand for health care 36–8
 demand management 99, 104
 demand-side financing 170
 dementia 289–92
 Department of Health (DOH) 86, 96, 107, 144, 233, 238, 243–6, 247, 250, 252, 321, 324
 Department of Health, Social Services and Public Safety 249, 250
 Devadasan, N. 169, 170
 Di Matteo, L. 131, 139
 diagnosis-related group (DRG) system xiii, 84, 138, 140–141
 Dickie, M. 303, 305
 Dickinson, H. 239, 242, 243
 diffusion of technology xiii–xiv
 definition of diffusion 179–82
 health care technologies 182–3
 modelling 183–5
 new pharmaceuticals 186–7
 physical capital 185–6
 policy implications 188–9
 surgical procedures 187–8
 disability-linked annuities 268
 discrete event simulation 101–2
 distribution of health care 14–15
 Dixon, A. 85, 90–91, 114
 Dolman, A.B. 284
 Donabedian, A. 51, 152
 Doran, T. 144, 148–50, 152–3
 Dowding, K. 79, 81
 Downs, A. 302, 308
 Drechsler, D. 166, 167, 168
 drug lags 196–213
 Duggan, M. 186, 190

 ECHP (European Community Household Panel Survey) 10, 12
 economic factors in health, *see* socioeconomic gradient in health
 economic directions 318–19
 education-related inequalities 11–12
 efficiency 83–4, 88–9
 Egypt 41–2, 44
 Eikemo, T.A. 7, 12
 Ekman, B. 43, 168
 Elgazzar, H. 43, 44, 45
 Ellis, R.P. 45, 140

 EMEA (European Medicines Agency) 196
 and global harmonisation 202–5
 and new generic legislation in Europe 210
 sub-analysis 205–7
 emergency care 51
 emotional agents 318–19
 employment-related insurance 272–3
 Entabeni Project 20, 23–4
 actionable lessons from 29–31
 Alma-Ata Declaration 21–2
 analysis of 28–9
 goals 24–7
 objectives achievement 31–2
 entry and exit of suppliers 84
 environmental determinants 14
 Epstein, A. 152, 204
 equity and choice 85–6, 90–91
 Esping-Andersen, G. 38, 39
 Ettner, S.L. 8, 148
 EU-SILC (European Union Survey of Income and Leaving Conditions) 10, 115, 118
 Europe
 generic legislation 210–211
 launch delays 204–5
 and pharmaceutical innovation 201–2
 projections of ageing population 221
 European Commission (EC) 113, 228
 European health care systems
 choice and competition 79–80, 86–8
 education-related inequalities 11–12
 measuring access to 113–23
 European Union (EU), role of 13–14
 Evans, R.G. 36, 83, 316
 Evans, W.N. 186, 305
 expenditure, *see* health care expenditure
 external change agents (ECAs) 20, 24–9, 30
 extrinsic values of choice 79
 efficiency 83–4, 88–9
 equity 85–6, 90–91
 quality 84–5, 89–90

 Fairbrother, G. 145, 153
 Felder, S. 223, 225, 228
 Feldman, S. 80–81
 Felt-Lisk, S. 150, 155
 Fernández, J.-L. 36, 114, 258
 FFSA 259, 265
 financial incentives 144–56
 Finkelstein, A. 259, 262–6, 269–70, 274–5
 Finucane, M. 301, 308
 Fischhoff, B. 301, 303
 Forder, J. 236, 258, 268
 forgone care, *see* unmet need
 Foubister, T. 114, 260, 266, 267
 Frank, R.G. 144, 148, 318, 319

- Fuchs, V.R. 131, 134–5, 178, 189, 222, 318–19
 full long-term care insurance 267
- gaming 108, 149, 152–3
- Gaynor, M. 85, 89
- GDP (gross domestic product)
 average expenditure by age group 132
 health care expenditure growth relative to
 GDP growth 137
 health care expenditure per capita (HE) 134
 health expenditure as percentage of 131
 per capita growth 130
- generic products 196
 EMEA (European Medicines Agency) 210
 European generic legislation changes 210
 evolution of median delays 207–8
 Hatch–Waxman Act and improved generic
 access 209
 lags across markets 210–211
 stringency in MA regulations and US drug
 lag 208–9
 US generic legislation changes 210
- Gerdtham, U.-G. 5, 8, 9, 15, 131, 133
- Gerking, S. 303, 305
- German model of long-term care 241–2, 259
- Getzen, T.E. 131, 221
- Gibbs, A. 26, 28
- Glasby, J. 234, 247
- Glendinning, C. 234–9, 241–2, 243, 247–9, 253
- Glickman, S.W. 147, 149
- Goodwin, N. 234, 320
- Gottret, P.E. 161, 162, 163, 165, 166
- Grabowski, H.G. 183, 200
- Grady, K.E. 145, 153
- Gravelle, H. 99, 104, 321
- Gray, A. 137, 223, 224, 225, 227, 228, 230
- Griffiths, C. 284, 286, 290
- Griliches, Z. 189, 190
- Grossbart, S.R. 146, 147, 149
- Grossman, M. 5, 36, 37
- Guilleen, A. 79, 86, 88
- Gulliford, M. 113, 114, 153
- Haberman, S. 292, 293
- Häkkinen, U. 223, 230
- Ham, C. 100, 247
- Harrison, A. 97, 99, 104, 106
- Hatch–Waxman Act 1984 196, 201–2, 209, 210
- Health Act Flexibilities (HAFs) 245, 249
- health and social care divide *xiv*, 233
 bridging the divide 239–40
 causes 233–5
 consequences for service users 235–9
 evidence base 248–51
 integration of services 246–8
 macro-level 240–245, 251–2
 meso- and micro-levels 245–6, 252
- health care expenditure *xiii*, 141–2
 controlling 140–141
 growth in 129–30
 increasing volume and its causes 136–40
 optimal levels 142
 role of income and prices 130–136
- health care system goals 3, 52
- health care technology *xiii*, 177–8, 182–3
 diffusion of *xiii–xiv*, 179–82, 183–9
 and expenditure 138–40, 178–9
- health economics 315–16, 319
- health financing policy 160–171
- health inequalities *xi*, 3–4
 challenges 15–16
 data requirements 7–12
 measurement 6–7
 policy 13–15
 sources of 4–5, 15
- health insurance schemes 43, 45–6
- health maintenance organisations (HMOs)
 138, 190
- health measures 7–10
- health-related behaviours, *see* risk research and
 health-related behaviours
- Health Select Committee 237, 238
- Health Service Ombudsman 237, 238
- health service utilisation, *see* utilisation
- health technology assessment (HTA) 140–141
- health variables 7–9
- Healthcare Commission 98, 108
- Healy, J. 50, 52, 113
- Heenan, D. 246, 250, 253
- Henwood, M. 237, 238, 244
- Hernández-Quevedo, C. 5, 10, 12, 45, 118
- heuristic norms 319
- Hillman, A.L. 147, 150, 155, 186
- Hiscock, J. 234, 235
- HIV/AIDS 20–32
- HIVAN 20–29
- HM Government 239, 240, 243, 244
- Hogan, C. 229, 230
- Holdenrieder, J. 262, 275
- holistic theoretical framework 317–18
- Hood, C. 105, 106, 108
- horizontal integration 247
- Horrigan, D.R. 148, 149, 150, 153
- hospital waiting-time policy *xii–xiii*, 94–7,
 108–9
 accounts of waiting 97–103
 average waiting times in M/M/c queue 98
 elective hospital admission 105
 England's inpatient waiting times 96, 107
 from GP referral to first appointment 106

- newspaper headlines 95
 UK cross-country comparison 103–6
 value of reductions 107–8
 hospitalisations for ACSCs 53–5, 64–75
 household financial burden 43
 Hsiao, W.C. 168, 170
 Hsieh, C.R. 303, 305, 309
 Huckman, R.S. 139, 188, 189, 190
 Hudson, B. 246, 249
 Hurley, T.M. 299, 303, 310
 Hurst, J. 89, 95, 97

 Idler, E.L. 8, 114
 Ikegami, N. 234, 241
 immediate needs annuities 267–8
 incentives
 for community participation 32
 impact on diffusion of technology 141
 for improved quality 84–5, 144–56
 physicians' 320–321, 323
 provider 102–3, 109
 tax 270
 income elasticities 130–133
 income-related inequalities 6–7, 12, 118
 indicators xiii
 ambulatory care 52–6, 60–61
 health status by national income level 41
 objective, for health 9
 for P4P systems 151–2, 156
 unmet need as 115–23
 induced demand 99
 insurance 263
 physician 316
 provider 168
 supplier 138
 inequalities, health inequalities
 INESE 267, 276
 information
 asymmetry 83–4, 85, 315–16
 availability of, and risk 300–301, 303
 and Bayesian learning framework 303–6
 and diffusion process 186–7
 role in relation to risk perceptions 301–9
 informed decision-making model 317
 innovation stimulus 201–2
 Institute of Medicine 52, 53, 54
 insurance
 coverage and utilisation of health care 45,
 137–8
 private health insurance (PHI) 165–8, 171
 private long-term care insurance xiv, 258–75
 intrinsic values of choice 79, 81–3

 Jakab, M. 168, 169, 170
 Janssen, F. 283, 284, 289

 Japan
 model of long-term care 241–2
 pharmaceuticals 201–3, 205, 209, 211, 212
 Jensen, G.A. 266, 270, 271, 275
 Johannesson, M. 5, 8, 15, 187
 John, P. 79, 81
 Johnston, D.W. 8, 9
 Johri, M. 247, 248, 249, 251, 252
 joint working 245–6, 249–51
 Jones, A.M. 7, 8
 Jönsson, B. 133, 200
 Jowett, M. 44, 170
 Jutting, J. 166, 167, 168

 Kahneman, D. 100, 299, 300, 303, 308, 309
 Kaplan–Meier (KM) survival estimates 198–9,
 200, 202–3, 207–9, 211
 Karshenas, M. 40, 41, 190
 Kessler, D.P. 89, 188, 196, 264
 Klein, R. 38, 90
 Knapp, M. 36, 43, 289
 Knickman, J.R. 50, 51
 Kodner, D.L. 242, 243, 246, 247, 248
 Koolman, X. 12, 118, 120
 Kovner, A.R. 50, 51
 Kramer, M. 131, 319
 Krishnan, C. 168, 169, 170
 Kunst, A.E. 11, 283, 284, 289
 Kyle, M.K. 195, 204, 210

 Labour government 81, 85–6, 103, 245–6
 Laditka, S.B. 69, 230
 Lafortune, G. 118, 230
 Lagergren, M. 223, 225, 228
 Lart, R. 246, 247, 248
 launches 195–213
 delays by period of first launch 216
 delays for generic molecules 217
 launch times 197–8
 mean and median, over time 216
 Lawn, J. 20, 22, 23
 Le Bihan, B. 264–5, 267–70, 272, 275
 Le Grand, J. 5, 14, 79–80, 84–6, 90–91, 102,
 114, 316
 Lebanon 38, 41–2, 44
 Lee, R.H. 186, 221
 Legido-Quigley, H. 51, 52
 legislation
 adult social care 239
 generic 209–10
 Lester, H. 50, 51
 Leutz, W. 233, 246, 247, 248, 249, 250, 251
 Lewis, J. 233, 234, 235, 236, 237, 240
 liberal welfare state 38
 libertarianism 82

- Lichtenberg, F.R. 186, 190, 196
 Lichtenstein, S. 299, 302
 LifePlans 265, 266, 271, 276
 lifestyle 38
 Lindenauer, P.K. 147, 149
 Lindgren, B. 303, 305
 literature
 ACSH admissions and rates 56–60
 effects of payment for P4P policies 144–56
 health and social care divide xiv, 233–52
 hospital competition 90
 inequalities 5, 8–9, 11–12
 physician–patient relationship 315–16, 318, 320–321, 323
 technology diffusion 183–4, 185, 187
 Liu, J.T. 303, 305, 309
 Lloyd-Sherlock, P. 164, 165
 Local Strategic Partnerships (LSPs) 246
 Loewenstein, G.F. 298, 300, 301
 Logan, W.P.D. 283, 284, 285
 London Patient Choice Pilot (LPCP) 91
 long-term care
 defining 236
 expenditure 129, 224–5
 funding xiv, 237, 240–245
 health and social care divide 237–9, 252
 private insurance for 258–75
 by proximity to death 226
 long-term high needs 237
 low- and middle-income countries (LMIC),
 social health protection xiii, 160–171
 low-level needs 236–7
 Lubitz, J. 222, 224, 225, 226, 230
 Luft, H.S. 182, 183
 Lundborg, P. 303, 305, 309, 310
 Lundin, D. 187

 M/M/c queue 98–9
 MA regulations 199–201, 208–9
 Mackenbach, J.P. 12, 285
 Magan, P. 54, 66
 magnetic resonance imaging (MRI) 184–5,
 185–6
 Mandelstam, M. 236, 252
 Marmot, M. 3, 5, 7, 37
 Marshall, M.N. 85, 152
 Martikainen, P. 222, 225, 226, 230
 Martin, C. 264, 265, 267, 268, 269, 270, 275
 material factors 14
 Mayhew, L. 266, 268
 McClellan, M.B. 89, 179, 185, 187, 188
 McCoy, D. 20, 22
 McDonald, R. 152, 154
 McGraill, K. 223, 224
 McGuire, A. 139, 190
 McGuire, T.G. 140, 314, 316, 320
 McIntyre, D. 113, 114, 160
 McKee, M. 50, 52, 54, 113
 Means, R. 234, 235, 236, 237, 253
 measurement
 health inequalities 6–7
 socioeconomic gradient 10
 systems for P4P 151–3, 154
 medical recommendations, adherence to 322
 medical sociology 316–18
 medical technology, *see* health care technology
 Mediterranean models of health care 88
 meliorist stance 94
 Mellor, J. 262, 271, 275
 Middle Eastern countries 40–42, 44–6
 middle-income countries
 health policy in xii, 39–42
 social health protection xiii, 160–171
 Miller, T. 221, 293
 Millman, M. 53, 54
 Ministry of Health (MoH) 162–5, 234, 274
 miserabilist stance 94, 109
 Moghadam, V.M. 40, 41
 molecules, new 195–213, 216–17
 mortality trends xiv, 283–5
 Alzheimer's disease and dementia 289–92
 forecasting 292–3
 trend analysis in England and Wales 285–9
 Morton, A. 98, 99
 Mossialos, E. 3, 166, 170
 Mur-Veeman, I. 233, 243
 Murphy, M. 222, 225–6, 230, 283–6, 293
 Murray, C.J.L. 9, 36, 283

 Nair, Y. 24, 26
 National Audit Office 97, 103
 national health insurance (NHI) 161
 purchasing and provision of health care 163
 revenue collection 161–2
 risk pooling 162–3
 National Health Service (NHS)
 equity of 90–91
 funding and responsibilities 233–5, 243–5
 hospital waiting times 96, 100–101, 105, 107–8
 integration of services 246
 internal market reforms 90
 long-term care 236, 237–9
 professionals' contracts of employment 102–3
 national income level
 health status indicators by 41
 total health expenditure by 40
 National Institute for Clinical Excellence (NICE) 104, 141, 214

- neoclassical economics 179, 298, 310
 New, B. 97, 104
 new chemical entities (NCE) 195
 new molecular entities (NMEs) 201
 Newhouse, J.P. 44, 131, 137–8, 140, 178, 185, 318–19
 Newman, J.F. 36–7, 44
 NHS Choices 250, 253
 Nolte, E. 52, 54
 Normand, C. 164, 165
 Northern Ireland
 bridging the divide 250, 251
 waiting times 105–6
 Norton, E.C. 147, 154, 224, 227, 262, 266
 Nummela, O.P. 7, 8
- obesity 12
 O'Donnell, O. 16, 43
 OECD 130, 132, 186, 228
 Office for National Statistics (ONS) 227, 287, 289
 Oliver, A. 3, 233
 Omran, A.R. 283, 285
 OR/MS technique 98
 out-of-pocket payments 42, 43, 45, 241
 outpatient care, *see* ambulatory care
 Ouwens, M. 247, 248
 Oxley, H. 136, 178
- P4P (payment for performance) xiii, 144–5
 clear communication 155, 156
 data and measurement systems 151–3, 154
 design parameters 145, 155
 effective 144–5, 156
 lack of evidence for evaluation 151
 magnitude and type of payment 149–51, 154–5
 type of service targeted 147–9, 154
 units of assessment 145–7, 154
 PACE (Programme of All-inclusive Care for Elderly People) 248
 Palmer, N. 43, 160
 patent term restoration 202
 paternalism 317
 patient behaviour account of waiting 99–100, 104
 patient selection 108, 149, 152–3
 Pauly, M.V. 136, 166, 167, 168, 170, 266
 payments structure 84
 Payne, G. 222, 223
 Pearson, M. 234, 235
 percutaneous transluminal coronary angioplasty (PTCA) 139, 141, 187–8, 189, 190
 performance measurement 50, 51, 152; *see also* measurement
 performance payment, *see* P4P (payment for performance)
 Permanand, G. 195, 200
 Petersen, L.A. 144, 147, 154, 155
 pharmaceutical corporations, international
 launch strategies 195–6, 212–13
 data 196–7
 definitions 197–8
 generic products adoption trends 207–11
 innovation adoption trends 198–207
 pharmaceutical innovation
 EMEA 202–7
 evolution of median delays 198–9
 Hatch–Waxman Act and stimulus for innovation 201–2
 stringency in MA regulations and US drug lag 199–201
 pharmaceuticals diffusion 186–7
 Phelps, C.E. 44, 131
 Phelps, K. 249, 250
 physical capital technologies 185–6
 physician–patient relationship xiv, 314–15, 323–4
 and adherence to recommendations 322
 physician's incentives 320–321
 psychology and economics 318–19
 satisfaction with consultation and choice of provider 321
 theoretical models 315–18
 Pidd, M. 102
 Pohlmeier, W. 36, 37, 44
 Polder, J.J. 223, 224, 225, 228, 283, 292
 policy
 health financing 160–171
 hospital waiting-time xii–xiii, 94–109
 implications in transition economies xii, 39–42, 44–6
 implications of mortality 283–93
 implications of technology diffusion 188–9
 and patient choice 86–8
 and physician–patient relationship 320–322
 potential actions for health inequalities 14–15
 and risk perceptions research 309–10
 role of WHO and EU 13–14
 Pomey, M.-P. 95, 97
 population-based approach 15
 positivist approach 36
 PPP (purchasing power parity) exchange rates 133
 Preker, A. 160, 166, 167
 Preston, S.H. 15, 285, 286
 primary care 51

- primary health care (PHC) in South Africa 20–32
- private health insurance (PHI) 165–6, 171
- purchasing and provision of health care 168
- revenue collection 166
- risk pooling 166–8
- private long-term care insurance xiv, 258–60, 274–5
- barriers to 261–6
- products 266–8
- public sector influence 269–74
- rationale for 260–261
- relationship with public financing 268–9
- process account of waiting 100–102, 104–5
- production account of waiting 97–9, 104
- Productivity Commission 178, 189
- profit maximisation alternatives 319
- Propper, C. 83, 89–90, 99, 104, 106–8, 320
- prospect theory 299–300
- provider incentive account 102–3, 105–6
- provider performance, *see* P4P (payment for performance)
- psychological directions 318–19
- psychological expected utility (PEU) theory 318–19
- psychosocial factors 14
- public long-term care system 269–70
- compulsory private insurance 273–4
- encouraging demand for insurance 270
- encouraging employment-related insurance 272–3
- and long-term care risk 271
- promoting awareness of risk 271–2
- tax incentives 270
- Quality and Outcomes Framework (QOF) 152–3, 321
- quality of care xi
- and choice 84–5, 89–90
- impact on 146–7
- measuring, definitions and dimensions 51–3
- queueing theory 98–9
- R&D
- activity of pharmaceutical companies 186–7, 201–2, 212–13
- expenditure 141–2
- Rabin, M. 300, 306
- Ramsay, A. 247, 248, 249
- Rannan-Eliya, R. 43, 45
- Rebba, V. 259, 268, 270, 271, 272, 275
- Regen, E. 249, 250
- regulatory environment for pharmaceutical corporations 195–213
- relative-income hypothesis 15
- Renshaw, A.E. 292, 293
- reporting bias 9–10
- Rifkin, S. 21, 24, 32
- Riley, G.F. 226, 230
- risk assessment with intuitive feelings 300–301
- risk perception conceptual framework 306–9
- risk pooling 43, 259
- community health financing 169–70
- national health insurance (NHI) 162–3
- private health insurance (PHI) 166–8
- social health insurance (SHI) 164–5
- risk research and health-related behaviours xiv, 297–8, 310–311
- conceptual framework 306–9
- implications for health policy 309–10
- role of information 301–6
- theoretical context 298–301
- Roland, M. 50, 51, 122, 321
- Romeo, A.A. 186, 190
- Roos, N.P. 223, 224
- Rosenthal, M.B. 144–5, 147–50, 152, 154
- Roski, J. 145, 148, 153
- Roudaut, N. 262, 265, 266, 271, 275
- Salas, C. 8, 224
- Sanders, D. 22, 23
- Savage, L.J. 298–9, 306
- Savedoff, W. 165, 166, 167, 168
- Schaay, N. 22, 23
- Schaber, P.L. 262, 266, 275
- Schieber, G. 131, 134, 161–3, 165–6, 170
- Schoen, C. 79, 123
- Schulz, E. 223, 225, 228
- Scitovsky, A.A. 222, 225, 283, 292
- Scotland
- and long-term care 236, 242–3
- waiting times 105–6
- Scott, A. 314, 315
- Scott, I.A. 144, 146
- Scott, K. 20, 21, 26, 30
- Secretary of State for Health 233, 237, 244
- Sekhri, N. 165, 166, 167, 168
- Serup-Hansen, N. 223, 228
- Seshamani, M. 137, 223–5, 227–8, 230
- SEWA scheme 169
- SHARE (Survey of Health, Ageing and Retirement in Europe) 10, 11, 115, 118–19, 120–121, 122, 123
- shared decision model 317
- Sheiner, L. 186, 227
- Shen, Y. 89, 152
- Shogren, J.F. 299, 303, 310
- short-term needs 236–7, 243–4, 245
- Shum, M. 184, 187
- Siciliani, L. 89, 95, 97, 104, 122

- Sikka, R. 147, 148
 SIPA 248
 Skinner, J. 190, 213
 Sloan, F.A. 180, 187, 190, 262, 266, 302
 Slovic, P. 299, 301, 308, 309
 Smith, J.P. 5, 8
 Smith, P.C. 51, 52, 98–9, 113, 144, 146, 152
 Smith, S. 139, 178
 smoking 12
 social and health care divide xiv, 233–52
 social-democratic model 39
 social health insurance (SHI) 163, 171
 purchasing and provision of health care 165
 revenue collection 163–4
 risk pooling 164–5
 social health maintenance organisations (SHMOs) 248
 social health protection xiii, 160–171
 socioeconomic gradient in health 3–4
 measurement 10
 socioeconomic status 5, 12
 sources of 4–5, 15
 in transition economies 43–4
 South Africa xi–xii, 20–21
 health and health care in 22–3
 see also Entabeni Project
 South African Department of Health 22, 24, 30
 specialty care 51
 Spillman, B.C. 224, 226
 Staiger, D. 190, 319
 star rating system 105
 state-funded systems 268–74
 Stavropoulou, C. 319, 322
 Stearns, S.C. 224, 227
 Steel, N. 148, 152
 Stevenson, D.G. 270, 276
 Stoneman, P. 179, 180, 182, 189, 190
 Street, A. 84, 106
 Stum, M.S. 262, 266, 275
 supplementary long-term care insurance 259, 267, 271
 supply barriers to long-term care insurance
 adverse selection 262–3
 insurance-induced demand 263
 uncertainty 261
 surgical procedures diffusion 187–8
 Survey of Health, Ageing and Retirement in Europe, *see* SHARE
 systems view of hospital 101
 Tabeau, E. 292, 293
 Taleyson, L. 264, 266
 target-oriented objectives 30
 tax-funded national health insurance (NHI) 161–3
 tax incentives 270
 TECH 141, 179, 188
 technology, *see* health care technology
 Thai Health Card scheme 168, 169
 Thalidomide 199–200
 Thomson, S. 81, 164, 165, 166
 Tickle, L. 292, 293
 time-to-failure events 197–8
 Timmer, E.J. 222
 Titmuss, R.M. 38, 39
 top-up long-term care insurance 259, 267, 271
 Town, R. 89, 145, 148
 Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement 201, 203
 transition economies 35–6
 access to care and the welfare state 38–9
 demand for health care 36–8
 gaps in health service utilisation 44
 gaps in household financial burden and health 43
 health policy in 39–42
 household payments for health care 43
 policy implications 44–6
 Tumlinson, A. 262, 273, 276
 Tversky, A. 299, 300–301, 303, 308–9
 Ulrich, V. 36, 37, 44
 UNAIDS 22, 30
 United Kingdom, health and social care divide xiv, 233–52
 unmet need 113, 122–3
 prevalence of 115–18
 reporting and utilisation of care 118–22
 user charges 83, 114, 166, 243, 250
 utilisation
 behavioural model of 36–7
 causes of increasing 136–40
 gaps in health service 44
 and insurance coverage 45, 137–8
 and reporting forgoing care 120–122
 vaccine-preventable ACSCs 54
 value for money of waiting-time reductions 107–8
 van Doorslaer, E. 6, 8–9, 12, 37, 43–4, 114, 160
 vertical integration 168, 247, 248
 Viscusi, W.K. 298–300, 302–6, 308–9, 311
 volume of health care, *see* utilisation
 vulnerable populations 15, 44–5
 Wagstaff, A. 5, 6, 7, 36–7, 44, 160, 162–5
 waiting-time policy, *see* hospital waiting-time policy

- Wales
 waiting times 105–6
 see also mortality trends
- Wanless, D. 97, 107, 179, 221, 223, 227, 229,
 234–5, 238–42
- Weber, W. 229, 230
- welfare state 15, 38–9, 233, 235
- welfarist argument for choice 82
- Whitehead, M. 9, 113
- Wiener, J.M. 36, 260, 264, 270–273
- Wilkinson, R. 5, 14, 15
- Willcox, S. 95, 106
- Windle, K. 251, 252
- Wittner, P. 209, 210
- World Bank 35, 39, 40
- World Health Assembly 160, 161
- World Health Organization (WHO) 3, 13–14,
 20–24, 36, 41, 43, 52, 160, 169, 170,
 283–4
- World Health Survey 9, 10
- Yates, J. 95, 102
- York, N. 144, 146
- Young, G.J. 144–5, 147, 149–51, 154–5
- Zweifel, P. 137, 167–8, 170, 182–4, 223, 228